HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3

• http://ow.ly/zQ7B50F3Gag

🤜MTX safe from kidney perspective if baseline CrCl 40+ 🤜Potential for immunomodulation to prevent/slow progression to CKD? Deserves dedicated studies @Nephro_Sparks

Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w

How does MTX affect kidney function/adverse events? Pre-specified analysis of DBRCT: MTX 15-20mg/wk (n=2391) vs. PBO (n=2395) both with folic acid over median f/u 23 months ✅We demonstrated kidney safety of MTX ⚡️⚡️Also a *suggestion* of LESS decline in eGFR for MTX than PBO https://t.co/SZXloLRmnj

• https://twitter.com/jeffsparks/status/1400758056401747971

PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy? ⭐️Mean C3 ⬆️28% compared to 1st trimester ⭐️Mean C4 ⬆️ 11% compared to 1st trimester @RheumNow

#EULAR LB0003 Pfizer #COVID vax immunogenicity and safety in 686 rheum pts in Israel ⭐️Sero+ for COVID Ab 86% in RMD vs 100% controls ⭐️RTX lowest seropos of 39%, related to time of infusion ⭐️⬇️ with GC, ABA, MMF ⭐️ MTX not seen to significantly ⬇️ @RheumNow @rheum_covid

#POS0022 prosp study of CTZ pregnancies: 1392 preg w/1425 outcomes @UCBUSA database 88.4% live births, 10.5% preg loss, 0.8% still birth 2.4% congen malform (w/2.1% major) Preg loss⬅️Crohn's, NSAIDS, MTX Preterm labor⬅️GCs, maternal infx ⬇️birth wt⬅️RA & GCs @rheumnow #EULAR2021 https://t.co/qnNcDIz8Ge

#EULAR2021 and EULAR IQ Dr Jack Cush reviews highlight presentations from the first 3 days of EULAR 2021. https://t.co/BkHjhOUqNU https://t.co/4JS1yGiJHg

• https://bit.ly/3fS5SJX

Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD

2021 GRAPPA STRONG recs (cont'd): *⃣Crohn's Dz & UC: TNFi (not ETN), IL12/23i 🚫strong rec against IL17i 2021 GRAPPA CONDITIONAL recs for: *⃣ Uveitis: TNFi (not ETN), CyA *⃣ Crohn's Dz & UC: IL23i, JAKi, MTX OP0229 #EULAR2021 @RheumNow https://t.co/AWyKqSapWG

Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6

#OP0228 Phase 3 RCT on Risankizumab - KEEPsAKE 2 -PsA with 49% prior bDMARD 95% prior csDMARD: week 24 results PE: ACR20 51% active vs 26% on PLC PASI90: 55% active vs. 10% PLC #EULAR2021 @RheumNow https://t.co/UkZLcXTNnq